Skip to main content
. Author manuscript; available in PMC: 2012 Feb 15.
Published in final edited form as: Am J Cardiol. 2011 Feb 15;107(4):545–551. doi: 10.1016/j.amjcard.2010.10.013

Table 3.

Reasons of Termination during the 12-Week Treatment Phase

Reasons for Termination During
Acute Phase
Remission
Group
(n = 208 [22.5%])
Non-Remission
Group
(n = 194 [33.5%])
P-value
Patient withdrew 1 (0.5%) 4 (2.1%) 0.15
Patient lost to follow-up 4 (1.9%) 7 (3.6%) .30
Side Effect 13 (6.3%) 16 (8.3%) .44
Withdraw by study physician 5 (2.4%) 14 (7.2%) <.02
Noncompliance 19 (9.1%) 13 (6.7%) <.37
Death 3 (1.44%) 5 (2.58%) 0.42
Other 2 (0.9%) 6 (3.1%) .13